Overview

The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD)

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this trial is to compare the ability of two doses of OT-551 ophthalmic solution and drug-free solution to safely and effectively treat geographic atrophy associated with age-related macular degeneration.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Othera Pharmaceuticals
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- have a clinical diagnosis of GA in one or both eyes;

- be of non-childbearing potential

Exclusion Criteria:

- have GA secondary to any condition other than AMD in the study eye;

- have a BCVA of 20/200 or worse in the non-study eye;

- have a history of or current choroidal neovascularization in either eye, or the need
for any study eye anti-angiogenic therapy;

- have any ocular condition in the study eye that would progress during the course of
the study and could affect central vision or other ocular conditions that may be a
confounding factor in this study;

- need to wear contact lenses in the study eye during the study;

- had confounding ocular surgery in the study eye;

- have concomitant treatment with any systemic or ocular medication that is known to be
toxic to the lens, retina, or optic nerve;